BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27790998)

  • 1. Extracellular matrix stiffness causes systematic variations in proliferation and chemosensitivity in myeloid leukemias.
    Shin JW; Mooney DJ
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12126-12131. PubMed ID: 27790998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
    Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
    Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells.
    Pun CC; Lee KK; Chui YL
    Leuk Lymphoma; 2019 Dec; 60(12):3011-3019. PubMed ID: 31111759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
    Sontakke P; Carretta M; Jaques J; Brouwers-Vos AZ; Lubbers-Aalders L; Yuan H; de Bruijn JD; Martens AC; Vellenga E; Groen RW; Schuringa JJ
    Leukemia; 2016 Oct; 30(10):2064-2073. PubMed ID: 27125308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-101 suppresses the development of
    Gonzales-Aloy E; Connerty P; Salik B; Liu B; Woo AJ; Haber M; Norris MD; Wang J; Wang JY
    Haematologica; 2019 Jul; 104(7):e296-e299. PubMed ID: 30792205
    [No Abstract]   [Full Text] [Related]  

  • 6. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
    Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
    Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?
    Muntean AG; Hess JL
    Cancer Cell; 2008 Jun; 13(6):465-7. PubMed ID: 18538728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
    Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
    Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
    Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
    Chen L; Sun Y; Wang J; Jiang H; Muntean AG
    Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent.
    Yokoo M; Kubota Y; Motoyama K; Higashi T; Taniyoshi M; Tokumaru H; Nishiyama R; Tabe Y; Mochinaga S; Sato A; Sueoka-Aragane N; Sueoka E; Arima H; Irie T; Kimura S
    PLoS One; 2015; 10(11):e0141946. PubMed ID: 26535909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.
    Yang X; Pang J; Shen N; Yan F; Wu LC; Al-Kali A; Litzow MR; Peng Y; Lee RJ; Liu S
    Oncotarget; 2016 Jun; 7(24):36382-36394. PubMed ID: 27144331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
    Long J; Fang WY; Chang L; Gao WH; Shen Y; Jia MY; Zhang YX; Wang Y; Dou HB; Zhang WJ; Zhu J; Liang AB; Li JM; Hu J
    Leukemia; 2017 Dec; 31(12):2761-2770. PubMed ID: 28462918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the UBA2-WTIP fusion gene in acute myeloid leukemia.
    Lu X; Zhuang H; Yu Q; Zhang X; Wu Z; Zhang L; Xu Y; Wu B; Yang L; Ma A; Gan X; Yu X; Shen J; Xu R
    Exp Cell Res; 2018 Oct; 371(2):409-416. PubMed ID: 30179602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
    Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
    Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels.
    Wang C; Tong X; Yang F
    Mol Pharm; 2014 Jul; 11(7):2115-25. PubMed ID: 24712441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
    Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
    Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro.
    Jiang MJ; Dai JJ; Gu DN; Huang Q; Tian L
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):372-378. PubMed ID: 28986256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets.
    Carlet M; Völse K; Vergalli J; Becker M; Herold T; Arner A; Senft D; Jurinovic V; Liu WH; Gao Y; Dill V; Fehse B; Baldus CD; Bastian L; Lenk L; Schewe DM; Bagnoli JW; Vick B; Schmid JP; Wilhelm A; Marschalek R; Jost PJ; Miething C; Riecken K; Schmidt-Supprian M; Binder V; Jeremias I
    Nat Commun; 2021 Sep; 12(1):5655. PubMed ID: 34580292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.